Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DASH-2 Trial

The DASH-2 trial is now in development and funded by NIHR Research for Patient Benefit. This trial aims to randomise 1000 patients from 65 UK hospitals to desmopressin or placebo. Both DASH trials are collaborations with Professor Nikola Sprigg at the University of Nottingham.